{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:46:22Z","timestamp":1773773182616,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T00:00:00Z","timestamp":1355184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Oral contraceptives alone or in combination with antiandrogens are commonly used in the treatment for polycystic ovary syndrome (<jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content>). We aimed to determine the effects of ethinyl estradiol\/drospirenone (<jats:styled-content style=\"fixed-case\">EE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRSP<\/jats:styled-content>) plus spironolactone therapy on inflammation and cardiometabolic risk in <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Twenty\u2010three lean, normal glucose\u2010tolerant patients with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> and 23 age\u2010 and body mass index (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>)\u2010matched healthy control women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Androgens, high\u2010sensitivity <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010reactive protein (hs<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>), homocysteine, lipids, fasting insulin, and glucose levels during a standard 75\u2010g, 2\u2010h oral glucose tolerance test were measured. Patients with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> were evaluated before and after receiving <jats:styled-content style=\"fixed-case\">EE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRSP<\/jats:styled-content> (3\u00a0mg\/30\u00a0\u03bcg) plus spironolactone (100\u00a0mg\/day) for 6\u00a0months. Healthy controls were evaluated at baseline only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>hs<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>, homocysteine, lipids, insulin and glucose levels were similar between patient and control groups at baseline. <jats:styled-content style=\"fixed-case\">EE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRSP<\/jats:styled-content> plus spironolactone increased hs<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> and homocysteine levels in patients with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> (0\u00b750\u00a0\u00b1\u00a00\u00b728 <jats:italic>vs<\/jats:italic> 1\u00b75\u00a0\u00b1\u00a01\u00b73\u00a0mg\/l, <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0&lt;\u00a00\u00b705 and 13\u00b71\u00a0\u00b1\u00a05\u00b72 <jats:italic>vs<\/jats:italic> 17\u00b76\u00a0\u00b1\u00a05\u00b73\u00a0\u03bc<jats:sc>m<\/jats:sc>,<jats:italic> P<\/jats:italic>\u00a0&lt;\u00a00\u00b705, respectively). <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>, waist\u2010to\u2010hip ratio, <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> HDL<\/jats:styled-content> cholesterol and triglycerides, and glucose tolerance did not change. Modified <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>erriman\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>allwey hirsutism scores, testosterone levels and free androgen index improved (9\u00b71\u00a0\u00b1\u00a04\u00b72 <jats:italic>vs<\/jats:italic> 6\u00b72\u00a0\u00b1\u00a03\u00b74, <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0=\u00a00\u00b7001; 80\u00b76\u00a0\u00b1\u00a031\u00b71 47\u00b78\u00a0\u00b1\u00a020\u00b73\u00a0ng\/dl, <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0&lt;\u00a00\u00b705; and 10\u00b75\u00a0\u00b1\u00a07\u00b74 <jats:italic>vs<\/jats:italic> 1\u00b71\u00a0\u00b1 0\u00b78, <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0&lt;\u00a00\u00b7001, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">EE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DRSP<\/jats:styled-content> plus spironolactone therapy in 6\u00a0months improves androgen excess in lean <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> women without any adverse effects on adiposity, glucose tolerance status or lipid profile. However, this combination increases hs<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> and homocysteine levels.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2265.2012.04466.x","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T15:41:27Z","timestamp":1339774887000},"page":"120-125","source":"Crossref","is-referenced-by-count":37,"title":["Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome"],"prefix":"10.1111","volume":"78","author":[{"given":"Ayla","family":"Harmanci","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Unit Department of Internal Medicine Hacettepe University School of Medicine Hacettepe Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nese","family":"Cinar","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Unit Department of Internal Medicine Hacettepe University School of Medicine Hacettepe Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyase","family":"Bayraktar","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Unit Department of Internal Medicine Hacettepe University School of Medicine Hacettepe Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent Okan","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Unit Department of Internal Medicine Hacettepe University School of Medicine Hacettepe Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmr025"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032049"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031867"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0628"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040967"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000052939.59093.45"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530130055028"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-5-199909070-00008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-007-0401-x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02019.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del407"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(03)00073-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1958"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2430"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0709"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0789"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041536"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(10)61645-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.05.044"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.10.016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.09.038"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031158"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625180600983082"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00982.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031780"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345529"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03483.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0618"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021142"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003233421202"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802713"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.12.013"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00425-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01690.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep459"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.09.034"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31816a2476"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-009-1169-y"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(92)90047-W"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.09.011"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(03)00034-2"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.05.069"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2012.04466.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2012.04466.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:29:32Z","timestamp":1700623772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2012.04466.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1365-2265.2012.04466.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04466.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,11]]}}}